Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the orally disintegrating tablet and standard tablet formulations of finasteride met bioequivalence criteria in fasting healthy adult male Han Chinese volunteers, although there was a significant difference in time to maximum concentration.

This study aimed to assess whether using minoxidil alongside nutritional cyclical supplements could boost hair regrowth without antiandrogens or enzyme blockers, focusing on hair root strengthening. Results are not reported.

Accurate method measures finasteride levels in human plasma using gas chromatography-mass spectrometry.

This study reviewed the publication trends and key findings on alternative therapies for androgenetic alopecia, highlighting the increasing research interest in dutasteride and nontopical minoxidil, while noting a lack of high-quality trials for nontopical minoxidil formulations.

This review concludes that finasteride and dutasteride are the most evidence-supported oral treatments for androgenetic alopecia, with dutasteride offering slightly greater hair count improvements and both affected by genetic response modifiers.

This study reviews the effectiveness and safety of finasteride and dutasteride for treating androgenetic alopecia, highlighting that dutasteride reduces DHT more deeply than finasteride, with genetic factors influencing patient response and both drugs being evidence-supported options for men and women.

This study developed a peptide-based topical delivery system that enhanced hair growth with reduced systemic exposure to finasteride, showing efficacy comparable to 5% minoxidil in vivo while using significantly less finasteride than oral doses.

This study found that Caesalpinia bonduc seed extracts significantly reduced prostate weight and improved prostate tissue morphology in Wistar rats with testosterone-induced benign prostatic hyperplasia.

This study developed a precise and sensitive HPLC-MS/MS method for analyzing the pharmacokinetics of perospirone hydrochloride in human plasma, establishing it as suitable for clinical studies.

This literature review reported limited and low-quality studies on Serenoa repens for androgenetic alopecia, suggesting it may be effective but less so than finasteride, and highlighted the need for better-designed research to confirm its utility.

In this study, XZYFD, a Traditional Chinese Medicine formulation, was found to improve androgenetic alopecia in a testosterone-induced mouse model by promoting hair regrowth, restoring follicular morphology, and modulating androgen metabolism, MAPK signaling, and lipid metabolism pathways, suggesting potential benefits for patients with metabolic dysfunction.

This study found that a low-dose intermittent finasteride regimen significantly reduced hirsutism scores in adolescent girls with PCOS or idiopathic hirsutism, with similar efficacy but potentially safer and less expensive than continuous administration.

This study reported that a subcutaneous injection formulation using PLGA microspheres to release finasteride stably achieved sustained monthly drug delivery without burst release in beagle dogs, with a dose of 16.8 mg identified as optimal for potential first-in-human trials.

This study found that both high-dose and low-dose finasteride significantly reduced hirsutism scores in women after 12 months, with the lower dose being safe and cost-effective.

This study reported that combined oral finasteride and topical 5% minoxidil treatment in men with male-pattern hair loss improved hair growth by initiating anagen in pre-existing but deficient follicles, yet the growth rates remained unchanged and did not normalize hair productivity.

In this study, low dose finasteride or dutasteride treatment was found to reduce prostate specific antigen levels in men with androgenetic alopecia, though levels sometimes remained stable or increased in those with low baseline PSA.

This study found that low-dose finasteride use in young men was associated with higher reporting of persistent sexual dysfunction, with some cases linked to suicidal ideation.

This study found that low-dose finasteride treatment in men with premature androgenetic alopecia decreased levels of 5α-reduced steroids, which may be linked to increased depression symptoms.

This article reviews multiple entries on the Androlog blog regarding finasteride use, concluding that a 1-mg dose does not adversely affect spermatogenesis or pose a risk during conception or pregnancy.

The authors concluded that while finasteride 1 mg affects prostate-related pathways, evidence is insufficient to prove clinical benefits for prostate outcomes compared to the established effectiveness of finasteride 5 mg.

This article reviews structured management strategies for diagnosing and treating hair and scalp disorders, offering clinical guidelines and emphasizing the importance of psychosomatic care and patient-therapist communication.

In this pilot randomized clinical trial, TRT combined with finasteride increased lean mass, muscle size, and bone mineral density without prostate enlargement in men with spinal cord injury, suggesting potential benefits for body composition and musculoskeletal health.

This study found that oral minoxidil was associated with short-term improvements in clinical severity for androgenetic alopecia, whereas oral dutasteride did not show significant early clinical changes in the six-month follow-up.

This case report describes a patient with lichen planopilaris who experienced remarkable hair regrowth at a previously scarred area after treatment with low-dose naltrexone and platelet-rich plasma, following minimal response to other therapies.

This study highlights the importance of clinicians understanding the effects of gender-affirming hormones like testosterone, estrogen, and antiandrogens on hair growth, to effectively diagnose and treat androgenetic alopecia in gender minority patients.

This review discusses current and emerging treatments for androgenetic alopecia, covering mechanisms, efficacy, and safety of both androgen-targeted and non-androgen-targeted approaches, but reports no new clinical results.

This review evaluates the use of 5α-reductase inhibitors in feminising hormone therapy, finding their additive feminising benefits unclear due to their specific action on testosterone conversion, with concerns highlighted regarding limited supporting evidence and safety signals, particularly for psychiatric and sexual effects.

This study suggests that a low daily dose of finasteride may be effective in reducing recurrent priapism episodes in children and adolescents with sickle cell disease, though larger controlled studies are needed to confirm these findings.

This article discusses the foundational concepts of nanotechnology and its contributions to dermatology and medicine, but does not present new research findings.

This study found that low-dose tamoxifen may effectively treat painful gynecomastia in patients receiving flutamide and finasteride for advanced prostate cancer.